Journal of Cancer Diagnosis
Open Access

Kidney cancer; Kidney biopsy; Renal cell carcinoma; Diagnosis; Nephrectomy; Clinical transplantology

Introduction

The best course of treatment for people with chronic renal disease is a kidney transplant. It enhances survival and quality of life. The incidence of rejection has significantly decreased since the introduction of novel immunosuppressive drugs for desensitisation, induction, and maintenance. These drugs do, however, also have negative and dangerous side effects. Patients who have had kidney transplants (KTR) frequently use medications that cause cytopenia. To avoid problems like cytopenia and prevent rejection, a careful balance must be struck. Cytopenia is frequent in people who have had kidney transplants. During the course of their transplant, twenty to sixty percent of KTR will experience one episode of neutropenia or cytopenia. Due to intensive maintenance immunosuppression and induction treatment, cytopenia is more common in the initial stage. Similar to thrombocytopenia, KTR will often experience the lowest platelet levels within the first three months of transplantation [1].

Numerous medications have been linked to cytopenia. These include tacrolimus, sirolimus, cotrimoxazole, antithymocyte globulin (ATG), ganciclovir/valganciclovir, enteric-coated mycophenolate sodium (EC-MPS), or mycophenolate mofetil (MMF). Serious cytopenia necessitates immediate intervention, which includes locating the offending medication and decreasing or halting it [2]. Such circumstances call for a well-rounded strategy. Rejection may result if immunosuppressive medicine is stopped suddenly. Similar to valganciclovir, trimethoprim-sulphamethaxazole can increase the risk of pneumocystis jirovecii or CMV infections. On the other side, severe neutropenia or leucopenia can cause opportunistic infections that can be fatal. This study will concentrate on medications linked to haematological cytopenia and how changing medication dosages or treatment plans can lessen these side effects [3].

Due to significant advancements in immunosuppressive medication therapy, the prevalence of acute rejection following kidney transplantation has significantly decreased. Long-term survival rates, however, remain stable despite recent gains in short-term survival rates, and increasing them in the future will continue to be difficult. Results of kidney transplantation are related to both immunosuppressive factors, such as rejection, and non-immunosuppressive factors [4], such as adherence and chronic kidney disease (CKD) after transplant. Immunosuppressive medication use, monitoring for adverse events, preventing infections, self-monitoring, physical exercise, regulating nutrition, and routine professional consultations are all required recipient self-management strategies. These various self-management demands are seen as important for preserving health and reducing the recurrence of CKD problems [5].

However, our earlier research revealed a negative correlation between self-management regimen adherence and time since transplantation, so we must constantly encourage efficient selfmanagement while taking into account the unique circumstances of each patient. In order to boost patients’ motivation to self-manage and to provide them honest feedback on their efforts, an evaluation scale is essential [6].

For kidney transplant recipients, there is an evaluation scale that has been shown to be valid and trustworthy. The measure has three components: self-care behaviours, patient-provider relationships, and problem-solving. The self-care behaviour part of this scale includes actions like taking medication, gauging the volume of urine, and feeling the transplant site but excludes CKD management. Minimising the recurrence of CKD problems is crucial for enhancing long-term results. Therefore, it is essential to provide reliable tools to assess self-management practises, including self-monitoring of vital signs, physical activity, and dietary management, which involve managing CKD. The new instrument also needs to be appropriate for usage in clinical settings and cover the recipient’s therapeutic behaviours [7].

We think that the creation of such a tool could be beneficial for both determining specific issues with an individual and gauging the success of self-management educational initiatives. Therefore, the goal of this study was to create and verify a novel self-management scale for kidney transplant recipients in order to enhance their long-term outcomes and stop CKD problems from recurring [8].

Discussion

With 4% of all new instances of cancer, kidney cancer is the sixth most prevalent malignancy worldwide. It affects more males than women, and as people get older, it becomes more prevalent. Although the precise aetiology of kidney cancer is unknown, a number of risk factors, such as smoking, obesity, high blood pressure, and specific hereditary disorders, have been found. Renal cell carcinoma (RCC), another name for kidney cancer, is a form of cancer that develops in the tissues of the kidneys [9]. It is one of the most prevalent types of cancer, and over the past few decades, its frequency has been rising. We will go over the numerous techniques for diagnosing kidney cancer in this review post. A physical examination and medical history are typically the first steps in the diagnosis of kidney cancer. In order to check for any anomalies, the healthcare professional may also request various blood and urine tests. Imaging studies to find the tumour are typically performed as the following step if these tests indicate the presence of kidney cancer [10].

Clinical transplantology is a specialty of medicine that is constantly developing. Effective organ and tissue transplantation is now achievable thanks to advances in surgical methods and immunosuppressive medication. Currently, experimental head and face transplants are being tried in addition to completing standard organ transplants. Over the past few decades [11], kidney transplantation has evolved into a normative clinical procedure. By not requiring haemodialysis or peritoneal dialysis, it significantly lowers mortality and enhances patients’ quality of life. Every year, more transplant surgeries, including kidney transplants, are done around the world. However, a big difficulty is the rejection of donated organs and tissues. The processes that enable the transplanted kidney to remain functional over the long term are still not fully understood [12].

Physical examination, urine volume, evaluation of albuminuria or proteinuria, serum creatinine, and estimation of glomerular filtration rate (GFR) based on serum creatinine are all used in the monitoring of transplanted kidneys. The most frequently utilised biochemical marker is serum creatinine levels, which rise late after damage and are not type-specific [13]. It is believed that it will probably play a role in deciding the long-term graft survival rate. Serum concentrations of this measure, however, are neither sensitive nor selective for gauging graft status. Additionally, the serum creatinine level is neither specific nor predictive because it cannot be used to anticipate or assess how a chronic injury will proceed. The gold standard for diagnosing rejection of a transplanted kidney, which can show interstitial fibrosis and tubular atrophy (IFTA) or chronic immunological damage, is still a renal biopsy’s histological analysis [14].

There is a lack of agreement about the histologic interpretation of the biopsies as well as the efficacy of treatment, and the biopsies are correlated with sampling error. Due to the variability of processes that underlie the same lesion, this method’s shortcomings include low sensitivity, low specificity, a lack of standardisation and quantitative thresholds, and sample mistakes. Alternative methods of diagnosis are being researched because of the high level of invasiveness of this treatment [15]. Imaging methods were also employed to assess kidney transplant rejection, including nuclear imaging, magnetic resonance imaging (MRI), contrast-enhanced ultrasonography (CEUS), and Doppler ultrasound to monitor renal graft perfusion. By keeping an eye on anti-HLA antibody titres and incorporating additional biomarkers, including the assessment of serum donor-derived cells, efforts are now being undertaken to reduce rejection rates [16].

The scientific articles from reliable sources like PubMed and the National Centre for Biotechnology Information (NCBI) are the foundation of this review. The search terms were biomarkers AND kidney AND transplant AND rejection OR neutrophil gelatinaseassociated lipocalin OR lipocalin-2 OR kidney injury molecule OR hepatitis A virus cellular receptor OR T-cell immunoglobulin mucin receptor OR C-X-C motif chemokine OR interferon--inducible protein OR clusterin [17].

The inclusion criteria state that patients receiving SPK transplants have terminal diabetic nephropathy, which necessitates dialysis before transplantation. The same pathogenic pathways that can cause diabetic retinopathy and neuropathy can also cause diabetic nephropathy. Therefore, retinopathy and diabetic neuropathy would be expected in these patients. In reality, candidates for SPK transplantation frequently and severely suffer from diabetic neuropathy. At the beginning of our trial, all patients had aberrant CART results. According to ADA guidelines, glycemic management was suboptimal with an HbA1C mean of 8.1% and a mean period of 25 years for T1DM progression. CAN and other microvascular problems associated with DM should therefore be present in this patient population [18].

Previous investigations have shown a small improvement in cardiovascular autonomic function following pancreatic transplantation. Some of them stated that CAN recovery appeared to be slower and more progressive than peripheral neuropathy improvement. Data from 23 recipients who had SPK were compared to 16 patients who underwent kidney transplantation alone (KTA) and were observed for 12 months. Both groups of transplant recipients exhibited improvements in autonomic nerve function one year following their surgeries [19].

Our 10-year prospective study demonstrates that after SPK transplantation, cardiovascular autonomic function greatly improves. As described in the Methods section, age-stratified levels were used to analyse each CART separately. To make the image easier to read, image 2 however, reflects normal values from 1985 as an interrupted line. Statistical analysis of the patient population was done using paired tests and descriptive statistics. The baseline values (preoperative values) were used as a comparison point for the mean values of the observed variables (analytical and functional tests) for each time period [20].

Conclusion

Physical examinations, medical histories, blood and urine testing, imaging studies, and biopsy procedures are frequently used to diagnose kidney cancer. The tumour’s size and location, the patient’s general health, and the cancer’s stage are only a few of the variables that affect these tests’ accuracy, advantages, and limitations. Patients should go over all of their alternatives with their doctor and get regular screenings if they are at an elevated risk.

Additional study is needed to develop novel and effective diagnostic or therapy strategies for RCC. The majority of traditional M2 markers (CD206, CD163) or the pan-macrophage marker CD68 has been used to measure macrophages in RCC to date. Nevertheless, employing these markers for a simple quantification of macrophages is insufficient for predicting the clinical course of the disease and may potentially be misleading given that CD68 was demonstrated to be expressed by ccRCC cells. These markers can be combined to develop a novel diagnostic approach with outstanding predictive ability.

They use markers like CD204, CD206, or folate receptor beta, which aren’t particularly selective for macrophages that are linked with tumours and are even less so for a particular kind of tumour. For the purpose of finding TAM markers that are specific to tumours, screening tests must be carried out. The results of these screens will make it possible to create targeting methods for reprogramming or eradicating TAM populations that sustain tumours.

Acknowledgement

None

Conflict of Interest

None

1. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, et al. (2008) BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15: 191-205.

Google Scholar, Crossref, Indexed at

2. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326.

Google Scholar, Crossref, Indexed at

3. Huang M, Yan C, Xiao J, Wang T, Ling R, et al. (2019) Relevance and clinic pathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagn Pathol 14: 74.

Google Scholar, CrossRef, Indexed at

4. Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, et al. (2012) BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42: 404-410.

Google Scholar, Crossref, Indexed at

5. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, et al. (2007) BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer 110: 1218-1226.

Google Scholar, Crossref, Indexed at

6. Hashimoto M, Heianna J, Okane K, Hirano Y, Watarai J, et al. (1999) Small cell carcinoma of the lung: CT findings of parenchymal lesions. Radiat Med 17: 417-21.

Google Scholar, Indexed at

7. Kazawa N, Kitaichi M, Hiraoka M, Togashi K, Mio N, et al.(2006) Small cell lung carcinoma: Eight types of extension and spread on computed tomography. J Comput Assist Tomogr 30: 653-61.

Google Scholar, Crossref, Indexed at

8. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, et al. (2003) Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4: 181-9.

Google Scholar, Crossref, Indexed at

9. Riquet M (1993) Anatomic basis of lymphatic spread from carcinoma of the lung to the mediastinum: surgical and prognostic implications. Surg Radiol Anat 15: 271-7.

Google Scholar, Crossref, Indexed at

10. Shin MK, Kim JW, Ju Y-S, (2011) CD56 and High Molecular Weight Cytokeratin as Diagnostic Markers of Papillary Thyroid Carcinoma. J Korean Med Sci 45.

Google Scholar, Crossref, Indexed at

11. Travis WD (2014) Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin 24: 257-66.

Google Scholar, Cross Ref , Indexed at

12. Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 17: 3.

Google Scholar, Crossref, Indexed at

13. Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, et al. (2002) Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 26: 1184-97.

Google Scholar, Crossref, Indexed at

14. Liu Y, Wang H, Li Q, McGettigan MJ, Balagurunathan Y, et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial. Radiology 286: 298-306.

Google Scholar, Crossref, Indexed at

15. Huang ZW, McWilliams A, Lui H, McLean DI, Lam S, et al. (2003) Near-infrared Raman spectroscopy for optical diagnosis of lung cancer. International Journal of Cancer 107: 1047-1052.

Google Scholar, Crossref, Indexed at

16. Bergholt MS, Zheng W, Lin K (2015) Characterizing variability of in vivo Raman spectroscopic properties of different anatomical sites of normal colorectal tissue towards cancer diagnosis at colonoscopy. Analytical Chemistry 87: 960-966.

Google Scholar, Crossref, Indexed at

17. Slipchenko M, Oglesbee RA, Zhang D, Wu W, Cheng JX, et al. (2012) Heterodyne detected nonlinear optical microscopy in a lock-in free manner. Journal of Bio photonics 5: 801-807.

Google Scholar, Crossref, Indexed at

18. Chen W, Tsai P, Chen Y (2008) Functional nanoparticle-based proteomic strategies for characterization of pathogenic bacteria. Analytical Chemistry 80: 9612-9621.

Google Scholar, Crossref, Indexed at

19. Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U, et al. (2008) Influences on pre-hospital delay in the diagnosis of colorectal cancer. Br J Cancer 98: 68-70.

Google Scholar, Crossref, Indexed at

20. Singh H, Daci K, Petersen LA (2009) Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. Am J Gastroenterol 104: 2543-2554.

Google Scholar, Crossref, Indexed at